SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance.
about
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversalDisrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?Activation of JNK triggers release of Brd4 from mitotic chromosomes and mediates protection from drug-induced mitotic stressNilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasBIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cellsNuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman's rank correlation analysisA new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsMEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells.Biphasic regulation of P-glycoprotein function and expression by NO donors in Caco-2 cells.LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition.Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach.p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.TLR signaling modulates side effects of anticancer therapy in the small intestine.Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation.Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infectionA review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.Inhibitory effects of PPARγ ligands on TGF-β1-induced CTGF expression in cat corneal fibroblasts.The use of novel selectivity metrics in kinase research.A novel synthetic compound MCAP suppresses LPS-induced murine microglial activation in vitro via inhibiting NF-kB and p38 MAPK pathways.Phosphorylation of Ago2 and Subsequent Inactivation of let-7a RNP-Specific MicroRNAs Control Differentiation of Mammalian Sympathetic Neuronsp38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes.Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways.Resveratrol reverses P-glycoprotein-mediated multidrug resistance of U2OS/ADR cells by suppressing the activation of the NF-κB and p38 MAPK signaling pathways.(S)-tetrahydroisoquinoline alkaloid inhibits LPS-induced arachidonic acid release through downregulation of cPLA2 expression.ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells.Inhibition of Jun N-terminal kinase (JNK) enhances glucocorticoid receptor-mediated function in mouse hippocampal HT22 cells.Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function.Annosquacin B induces mitochondrial apoptosis in multidrug resistant human breast cancer cell line MCF-7/ADR through selectively modulating MAPKs pathways.Regulation of MAPKs Signaling Contributes to the Growth Inhibition of 1,7-Dihydroxy-3,4-dimethoxyxanthone on Multidrug Resistance A549/Taxol Cells.Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II.Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.Increased glutathione and mitogen-activated protein kinase phosphorylation are involved in the induction of doxorubicin resistance in hepatocellular carcinoma cells.Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitroH1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein.Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line.ADAR1 controls apoptosis of stressed cells by inhibiting Staufen1-mediated mRNA decay.
P2860
Q21246014-F155AF77-3774-4F88-9A37-3ACFEC4D2F74Q28069761-087D7E42-18DC-468B-8AEE-7D9043BF67DAQ28483203-8D7B5191-BCA6-43FA-B73F-8B3B4E7399F1Q28483929-9468624A-34FF-410B-B9FA-E22B7F4EEDA7Q28485188-BB4710EC-6637-4D4D-87E5-F58126A83036Q28535696-7537C6A7-85BA-4837-BE4C-D016B1FD682AQ28541630-5B6F951E-96BA-48C6-A41B-061A2874428FQ30278995-7AE0B7D3-B862-4B71-9D35-515B9042D37EQ33394070-18FAD7FA-C029-42B3-A178-04B6B7CC0AACQ33567500-3CD04D94-4BE1-4D25-A8FD-9337F58B560AQ33792122-F2451009-51CC-4E51-B939-35475A7F3F1CQ33807661-C9F87C84-37EF-4372-9083-A4C55875633AQ34008781-318557F6-2120-422F-A82F-B6510BAFD3B6Q35114570-544B04B0-6A89-411D-BA1F-0480C9EBA401Q35125945-8BC95456-9F59-45BF-AE3B-F8526BE9214AQ35470183-816CE140-4053-4EC1-B165-FD63BD9C7DE3Q35609414-20D174A8-A809-44D6-BC4B-EC77FA25F0FDQ35868560-97E48551-EBD2-4265-A020-F8BE4E2B0BC8Q36005992-D646B6E3-F611-4674-9716-05C66410C163Q36240657-F0492094-9B3E-4DC9-B8E8-155E4396D0D8Q36644288-B85E68E8-A1A3-4E4E-B985-119DB626DC74Q36811735-2D1BBC92-C3AB-43AC-ABE1-849E66B665B2Q36993715-D31A30E6-D1C0-4300-8C46-4EF0B28B4873Q37407088-BC4BCE42-3DE7-443D-9467-7AACF724C53DQ37407335-7B55AE5A-987E-4426-B67E-1F4A2A3E11A8Q37462486-F6104E33-D34C-4C09-A1CE-62BA82F3E3C8Q37595188-416DF6C1-FD00-4161-AF0B-5DEC330E2BE1Q37836908-4A6D7278-D195-4ABC-B62D-42D64D6F7EBCQ38011895-574CD7D9-2CC3-4F56-A9AF-C44BD66FE711Q38334447-80631CE1-B005-47B7-A98A-799804FA07F9Q38346438-3A6E124F-DEEB-4649-9A5D-6A9364D17DA9Q38756234-24E1AD8B-3E61-42AD-AF2F-8CA7E94C6879Q38758665-E38F88D6-C5D9-4BC7-BC5A-05D989AF7364Q39245903-187AEC5A-C6F5-4FC1-B8B4-8E2F1F6C7683Q39294074-55B851E8-B4EB-4378-9C8F-E249F3EC4DC7Q39299662-5F34F2A6-1CFF-4A9D-9A3B-8C9AC4899951Q39531950-6CCC8AA5-6E9F-42AA-817F-CF6F9DDC2EC5Q39678602-4B6B5EC5-0765-4598-98BA-35C76276C65AQ40495935-C89716F3-05BD-4103-99ED-0D80D7634A8EQ42341765-7BD2DEDC-2986-4580-B6D2-6DC56901A0AA
P2860
SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
SB203580, a specific inhibitor ...... mediated multidrug resistance.
@en
type
label
SB203580, a specific inhibitor ...... mediated multidrug resistance.
@en
prefLabel
SB203580, a specific inhibitor ...... mediated multidrug resistance.
@en
P2093
P1476
SB203580, a specific inhibitor ...... -mediated multidrug resistance
@en
P2093
J Kvackajová
M Barancík
O Krizanová
V Bohácová
P356
10.1016/S0928-0987(01)00139-7
P407
P577
2001-08-01T00:00:00Z